A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant

Although PARP inhibitors (PARPi) now form part of the standard-of-care for the treatment of homologous recombination defective cancers, de novo and acquired resistance limits their overall effectiveness. Previously, overexpression of the BRCA1-∆11q splice variant has been shown to cause PARPi resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettitt, Stephen J., Shao, Nan, Zatreanu, Diana, Frankum, Jessica, Bajrami, Ilirjana, Brough, Rachel, Krastev, Dragomir B., Roumeliotis, Theodoros I., Choudhary, Jyoti S., Lorenz, Sonja, Rust, Alistair, de Bono, Johann S., Yap, Timothy A., Tutt, Andrew N. J., Lord, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473960/
https://www.ncbi.nlm.nih.gov/pubmed/37491606
http://dx.doi.org/10.1038/s41388-023-02782-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473960/
https://www.ncbi.nlm.nih.gov/pubmed/37491606
http://dx.doi.org/10.1038/s41388-023-02782-8

Ejemplares similares